Flos magnoliae total alkaloid extract and preparation thereof, and application of flos magnoliae total alkaloid extract in preparation of medicine for resisting PIK3CA mutation-containing tumor
Through the crushing and multi-step extraction process of magnolia, total alkaloid extracts with anti-tumor activity were prepared, which solved the problem of lack of treatment for PIK3CA mutant tumors in the prior art, and achieved effective inhibition of malignant tumors such as colorectal cancer. and the development of new targeted therapies.
Patent Information
- Application Number
- CN202411229208.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has not yet developed targeted therapeutic drugs for colorectal cancer with PIK3CA mutations, and Silkan has few research on anti-tumor, especially the application technology for tumors containing PIK3CA mutations has not been reported.
The steps of macadamia pulverization, pure methanol reflux extraction, distilled water ultrasonic dispersion, fractional extraction and re-extraction were prepared to anti-tumor total alkaloid extract containing PIK3CA mutant tumors. By adjusting pH value and purifying multiple extractions, anti-tumors were obtained. Active extract.
The extract significantly inhibits tumor cell proliferation, blocks cell cycle, inhibits cloning formation, induces apoptosis and inhibits cell migration. It has potential anti-tumor activity and can effectively inhibit the growth of PIK3CA mutant tumors, providing new targeted treatments Select to reduce drug toxicity and side effects.
Smart Images

Figure CN118903252A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of extracts, and in particular to a magnolia total alkaloid extract, a preparation method thereof, and an application thereof in preparing a drug for resisting tumors containing PIK3CA mutations. Background Art
[0002] Colorectal cancer is a malignant tumor of the digestive tract. According to the 2020 Global Cancer Data Estimates, colorectal cancer is the third most commonly diagnosed malignant tumor after breast cancer and lung cancer, with more than 1.9 million new cases, accounting for about 10% of all cancer incidence worldwide, of which 72% occur in the colon and 28% originate in the rectum; by 2030, the incidence of colorectal cancer will increase by 60%, and by 2040, the number of colorectal cancer patients will reach 3.2 million. Colorectal cancer is the second leading cause of cancer death, with more than 900,000 deaths worldwide in 2020, accounting for about 9% of all cancer-related mortality.
[0004] The main treatments for colorectal cancer include surgical resection, chemotherapy, radiotherapy, immunotherapy, and molecular targeted therapy. Currently, surgical treatment is the main treatment, especially for early-stage patients. However, for advanced or recurrent colorectal cancer, a combination of multiple treatments is often required to improve treatment outcomes and prolong survival. Commonly used chemotherapy drugs such as irinotecan, 5-fluorouracil, oxaliplatin, and capecitabine have certain effects in shrinking tumors and relieving symptoms, but are often accompanied by significant side effects. With in-depth research on the molecular mechanisms of tumors, targeted therapy has gradually become an important treatment. Targeted therapy drugs have better selectivity for malignant cells, can reduce damage to healthy cells, and improve treatment outcomes. In colorectal cancer, epidermal growth factor receptor and vascular endothelial growth factor pathways are common therapeutic targets.
[0005] For patients with colorectal cancer who have already developed distant metastasis, chemotherapy is the main treatment. Commonly used chemotherapy regimens include drugs such as irinotecan, 5-fluorouracil, oxaliplatin, and capecitabine. Compared with traditional chemotherapy drugs, targeted therapy drugs show better selectivity for malignant cells while minimizing damage to healthy cells, thereby improving efficacy and reducing toxicity. Targeted therapy has become an important treatment option. The most common targets for colorectal cancer are the epidermal growth factor receptor and vascular endothelial growth factor pathways. In addition, immunotherapy, as an emerging treatment strategy, has shown certain efficacy in the treatment of colorectal cancer.
[0006] Phosphatidylinositol-3-kinase (PI3K) is composed of regulatory subunits and catalytic subunits. It is a member of the heterodimeric lipid kinase family and can regulate a highly conserved signal transduction pathway, participating in physiological processes such as cell proliferation, adhesion, migration, apoptosis, and angiogenesis. These functions make PI3K play a key role in the occurrence and development of cancer and become an important marker of cancer progression. In addition, according to the Cancer Genome Atlas and the National Cancer Institute of the United States, PIK3CA is the second most mutated gene in major cancer types, with a mutation frequency of approximately 15% in colorectal cancer. PIK3CA mutations are closely related to the occurrence and development of colorectal cancer and resistance to targeted drugs, but no drugs targeting PIK3CA have been developed for the treatment of colorectal cancer.
[0007] Magnolia refers to the dried flower buds of Magnolia denudata Desr., Magnolia biondi Pamp. or Magnolia sprengeri Pamp. of the Magnoliaceae family. It is pungent and warm in nature, and enters the lung and stomach meridians. It has the effects of dispelling wind and cold and clearing the nose. It is often used to treat sinusitis, headaches caused by colds, nasal congestion and runny nose. The chemical components of Magnolia include lignans, alkaloids, volatile oils, phenolic acids and their derivatives. Magnolia has a wide range of pharmacological activities, including anti-allergic, anti-inflammatory, anti-angiogenic, anti-proliferative, etc. However, there are relatively few studies on the anti-tumor effects of Magnolia, especially for colorectal cancer and its potential target PIK3CA. Summary of the invention
[0008] For tumors containing PIK3CA mutations, no drug that can target PIK3CA for treating tumors has been developed. As a traditional Chinese medicinal material, there are few studies on magnolia in anti-tumor aspects, and there is no technical status for its use in the preparation of anti-tumor drugs containing PIK3CA mutations. The present invention aims to provide a magnolia total alkaloid extract targeting tumors containing PIK3CA mutations, and its preparation and use. The extract has the effect of targeting PIK3CA to inhibit tumor growth and metastasis.
[0009] In order to achieve the above object, the technical solution adopted by the present invention is:
[0010] The present invention provides a method for preparing a total alkaloid extract of magnolia officinalis for resisting tumors containing PIK3CA mutations, comprising:
[0011] (1) crushing magnolia flower, extracting with pure methanol by refluxing, filtering, and evaporating to dryness to obtain magnolia flower methanol extract;
[0012] (2) taking the magnesium methanol extract obtained in step (1), adding distilled water for ultrasonic dispersion, adjusting the pH value to obtain a first solution, and performing fractional extraction to obtain a magnesium extract;
[0013] (3) Taking the extract of magnolia officinalis extracted in step (2), adjusting the pH value to obtain a second solution, extracting again, and evaporating to obtain a magnolia officinalis total alkaloid extract for anti-tumor containing PIK3CA mutation.
[0014] The pure methanol reflux extraction is performed, and the amount of pure methanol solution added is 15 to 25 times the mass of magnolia, and the pure methanol reflux extraction time is 2 hours to 4 hours.
[0015] The distilled water is added for ultrasonic dispersion, and the amount of distilled water added is 10 to 20 times the mass of the magnolia methanol extract.
[0016] The graded extraction solvents are n-hexane, chloroform, ethyl acetate and n-butanol in sequence, the added amount of the extraction solvent is 1:1 in volume ratio with the first solution, and the number of extractions is 8-10 times.
[0017] The re-extraction solvent in step (3) is dichloromethane, the volume ratio of dichloromethane added to the second solution is 10-15:1, and the number of extractions is 8-10 times.
[0018] In step (2), the pH value is adjusted to 2-3, and in step (3), the pH value is adjusted to 9-11.
[0019] Furthermore, the pH adjusting agent in step (2) is any one of hydrochloric acid, acetic acid and carbonic acid.
[0020] Furthermore, the pH adjusting agent in step (3) is any one of sodium hydroxide, sodium carbonate and sodium bicarbonate.
[0021] The present invention provides a total magnolia alkaloid extract obtained by the above preparation method and having the function of resisting tumors containing PIK3CA mutation.
[0022] The use of the above-mentioned magnolia total alkaloid extract in the preparation of an anti-tumor drug containing PIK3CA mutation, wherein the tumor is selected from any one of breast cancer, endometrial cancer, cervical cancer, anal cancer, bladder cancer, and colorectal cancer.
[0023] Furthermore, the tumor is colorectal cancer.
[0024] The anti-tumor containing PIK3CA mutation is to inhibit tumor cell proliferation, block cell cycle, inhibit clone formation, induce cell apoptosis and inhibit cell migration, and inhibit tumor cell growth in vivo.
[0025] The anti-tumor drug containing PIK3CA mutation is any one of pills, granules, hard capsules, soft capsules, tablets, dripping pills and oral liquid preparations.
[0026] Compared with the prior art, the beneficial effects of the present invention are:
[0027] The preparation method of the total alkaloid extract of magnolia for tumors containing PIK3CA mutations provided by the present invention gradually purifies the total alkaloid components in magnolia through the steps of crushing, pure methanol reflux extraction, distilled water ultrasonic dispersion, graded extraction and re-extraction, and finally obtains an extract with anti-tumor activity, thereby ensuring the purity and activity of the extract, providing high-quality raw materials for subsequent development of anti-tumor drugs, and the extraction process is simple, the raw material source is wide, the cost is low, and the toxicity and side effects are small, and it is suitable for mass production.
[0028] The total alkaloid extract of magnolia obtained by the present invention has the effects of significantly inhibiting tumor cell proliferation, blocking cell cycle, inhibiting clone formation, inducing cell apoptosis and inhibiting cell migration and inhibiting the growth of tumor cells in vivo, has potential anti-tumor activity, can be further developed into new drug research and development, has a good inhibitory effect on PIK3CA mutant tumors, and develops new targeted therapeutic drugs for malignant tumors such as colorectal cancer. The extract can also be used as an auxiliary means of existing treatment plans to improve the treatment effect and reduce drug toxicity and side effects; it has good application prospects in the preparation of anti-colorectal cancer drugs and can provide more options for clinical colorectal cancer treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 This is a graph showing the inhibitory effect of Magnolia methanol extract on the proliferation of colorectal cancer cells SW480, SW620, HCT116, LoVo, Caco-2, and Colo205.
[0030] Figure 2 This is a graph showing the inhibitory effects of different extraction parts of Magnolia biondii methanol extract on the proliferation of colorectal cancer cells SW480, SW620, HCT116, LoVo, Caco-2, and Colo205, where A is n-hexane, B is chloroform, C is ethyl acetate, D is n-butanol, and E is water.
[0031] Figure 3 The inhibitory effect of chloroform on colony formation of colorectal cancer cells HCT116 and Caco-2, where A is HCT116, B is Caco-2, and MFC represents chloroform extract.
[0032] Figure 4 The diagram shows the cell cycle arrest effect of the chloroform fraction on colorectal cancer cells HCT116 and Caco-2, where A is HCT116, B is Caco-2, and MFC represents the chloroform extract.
[0033] Figure 5Diagram showing the regulatory effect of chloroform fraction on cell cycle proteins of colorectal cancer cells HCT116 and Caco-2, where A is HCT116, B is Caco-2, and MFC represents chloroform extract.
[0034] Figure 6 The diagram of the chloroform site inducing apoptosis of colorectal cancer cells HCT116 and LoVo, where A is HCT116, B is LoVo, C is the quantitative diagram of HCT116 cell apoptosis, D is the quantitative diagram of LoVo cell apoptosis, and MFC represents chloroform extract.
[0035] Figure 7 Diagram showing the regulatory effect of chloroform fraction on apoptosis proteins of colorectal cancer cells HCT116 and LoVo, where A is HCT116, B is LoVo, and MFC represents chloroform extract.
[0036] Figure 8 The inhibitory effect of chloroform on the migration of colorectal cancer cells HCT116 and LoVo, where A is HCT116, B is LoVo, and MFC represents chloroform extract.
[0037] Fig. 9 Diagram showing the regulatory effect of chloroform site on migration proteins of colorectal cancer cells HCT116 and LoVo, where A is HCT116, B is LoVo, and MFC represents chloroform extract.
[0038] Fig.10 The graph of the inhibitory effect of chloroform fraction on the growth of colorectal cancer cell CT26 in the Balb / c mouse transplant tumor model, where A is the tumor weight and B is the relationship between the tumor inhibition effect and the drug concentration.
[0039] Fig.11 The expression level of PIK3CA protein in colorectal cancer cell lines and its correlation with chloroform site IC 50 Correlation analysis diagram, where A is the expression level, and B is the expression level and IC in different cells 50 Correlation analysis diagram of .
[0040] Fig.12 This is a diagram showing the inhibitory effect of chloroform on p110α protein and downstream AKT pathway proteins in colorectal cancer cell HCT116.
[0041] Fig.13 A graph showing the inhibitory effect of the chloroform site on the growth of PIK3CA-knockdown colorectal cancer cell HCT116; wherein A is a graph showing the expression of PI3Kp110α, and B is a graph showing the inhibitory effect of the chloroform site on the growth of PIK3CA-knockdown colorectal cancer cell HCT116.
[0042] Fig.14The graph of the inhibitory effect of the chloroform site on the cell growth of PIK3CAH1047R, wherein A is the graph of PI3Kp110α expression, and B is the graph of the inhibitory effect of the chloroform site on the growth of PIK3CA wild-type and H1047R mutant cells.
[0043] Fig.15 UPLC-MS / MS total ion chromatograms of methanol extract and chloroform fraction, where A is the methanol extract and B is the chloroform fraction.
[0044] Fig.16 This is the heat map of the differential components of the total alkaloid extract and chloroform fraction of Magnolia officinalis.
[0045] Fig.17 This is a thin layer chromatogram of the total alkaloid extract of Magnolia officinalis.
[0046] Fig.18 The graphs show the inhibitory effects of the chloroform fraction and total alkaloid extract of Magnolia biondii on the growth of HCT116 nude mouse transplanted tumors, where A is a tumor photo and B is a tumor weight graph.
[0047] Fig.19 The graph shows the inhibitory effect of chloroform fraction and total alkaloids of Magnolia biondii on liver metastasis of HCT116 transplanted tumor, where A is a photo of the liver and B is a graph of the liver coefficient. DETAILED DESCRIPTION
[0048] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.
[0049] The instruments and materials used in the present invention are:
[0050] SW-CJ-IF clean bench (Suzhou Antai Air Technology Co., Ltd.); Ti-U inverted microscope (Nikon); MCO-18AC CO2 constant temperature incubator (Shanghai Panasonic Health Medical Equipment Co., Ltd.); HH-2A water bath (Beijing Kewei Yongxing Instrument Co., Ltd.); TD4C desktop centrifuge (Changsha Yingtai Instrument Co., Ltd.); micropipette (Eppendorf); BP211D electronic balance (Shanghai Guangzheng Medical Instrument Co., Ltd.); cell counting plate (Shanghai Qiujing Biochemical Reagent Co., Ltd.); culture plate (Costar); thiazole blue (Shaanxi Pioneer Biotechnology Co., Ltd.); crystal violet (Beijing Solebold Technology Co., Ltd.); propidium iodide (Shanghai Aladdin Biochemical Technology Co., Ltd.); RNase inhibitor (MedChemExpress, USA); Novocyte flow cytometer (Hangzhou Aisen Bioscience Co., Ltd.); BCA protein quantitative detection kit (Jiankangyuan Pharmaceutical Group Co., Ltd.); HB120-S LED metal bath (SCILOGEX, USA); Tanon EPS200 electrophoresis instrument (Shanghai Tianneng Technology Co., Ltd.); Tanon EPS 300 vertical electrophoresis tank (Shanghai Tianneng Technology Co., Ltd.); PVDF membrane (Sigma-Aldrich, USA); p110α antibody, GAPDH primary antibody and secondary antibody (Proteintech); ECL luminescent liquid (Anhui White Shark Biotechnology Co., Ltd.); Tanon 5200Multi automatic chemiluminescence image analysis system (Shanghai Tianneng Technology Co., Ltd.); Hipure Plasmid Mini Kits (Guangzhou Meiji Biotechnology Co., Ltd.); negative control plasmid and PIK3CA knockdown plasmid (Shanghai Jikai Biochemical Technology Co., Ltd.); PIK3CA mutant plasmid (Wuhan Miaoling Biotechnology Co., Ltd.); ampicillin (Sigma-Aldrich, USA).
[0051] Ultra-high performance liquid chromatography-tandem mass spectrometry: ExionLCAD (SCIEX, USA); methanol (Merck); acetonitrile (Merck); formic acid (Aladdin).
[0052] Tumor cell line used in the present invention
[0053] Colorectal cancer cell lines SW480, SW620, HCT116, LoVo, Caco-2 and Colo205 were purchased from the Cell Bank of Type Culture Collection Committee of the Chinese Academy of Sciences.
[0054] The preparation method of total alkaloids of Magnolia officinalis of the present invention is further described below in conjunction with the accompanying drawings and specific embodiments:
[0055] Example 1
[0056] The preparation method of the anti-colon cancer Chinese medicine magnolia extract is as follows: 20g of magnolia medicinal materials are crushed, 400mL of pure methanol is refluxed for 3h, and a rotary evaporator is used to spin dry, and the obtained dark brown extract is the magnolia methanol extract.
[0057] Example 2
[0058] On the basis of Example 1, 10 g of magnolia methanol extract was re-dissolved in 100 mL of distilled water, and 100 mL of n-hexane, chloroform, ethyl acetate, and n-butanol were used for graded extraction in sequence, and the extracts were dried using a rotary evaporator to obtain n-hexane fraction, chloroform fraction, ethyl acetate fraction, n-butanol fraction, and water fraction of magnolia.
[0059] Example 3
[0060] (1) 20 g of magnolia powder was refluxed with 400 mL of pure methanol for 3 h, filtered, evaporated to dryness, and 10 g of magnolia methanol extract was obtained;
[0061] (2) taking 10 g of the extract, adding 100 mL of distilled water for ultrasonic dispersion, adjusting the pH to 2 with 3% hydrochloric acid solution to obtain 100 mL of the first solution, and then extracting 8 times with 100 mL of ethyl acetate to obtain the ethyl acetate extract of Magnolia officinalis;
[0062] (3) Take the ethyl acetate extract of Magnolia officinalis, adjust the pH to 10 with a NaOH aqueous solution to obtain a second solution, add 1000 mL of dichloromethane for extraction, and evaporate the dichloromethane extraction solution to dryness to obtain 0.5 g of total alkaloid extract of Magnolia officinalis.
[0063] Example 4
[0064] This example investigates the inhibitory effects of the methanol extract of Magnolia officinalis in Example 1 and the n-hexane fraction, chloroform fraction, ethyl acetate fraction, and n-butanol fraction of Magnolia officinalis in Example 2 on colon cancer cells.
[0065] The MTT method was used to investigate the inhibitory effect of Magnolia officinalis extract and its different parts on the proliferation of colorectal cancer cells. 4 The cells were seeded into a 96-well plate at a density of 10 cells / well, and the plate was placed in a cell culture incubator overnight. On the next day, 20 μL of different concentrations of magnolia extract and different parts were added to each well and cultured for another 48 h. The original culture medium was discarded, and cell culture medium containing 0.5 mg / mL MTT was added, and the cells were incubated in a light-proof 37°C incubator for 4-6 h. The liquid in the culture wells was discarded, and 100 μL / well of DMSO solution was added. The well plate was placed on a shaker at 180 rpm and shaken for 15 min. The absorbance value of each well at 490 nm was detected using a spectrophotometer. For specific results, see the attached Figure 1 and attached Figure 2 shown.
[0066] By the attached Figure 1 The data show that the methanol extract of magnolia showed a good dose-effect relationship on 6 colorectal cancer cells. As the concentration of the methanol extract of magnolia increased, its inhibitory effect also increased accordingly.
[0067] By the attached Figure 2 The data shows that Figure 2 Among them, A is n-hexane, B is chloroform, C is ethyl acetate, D is n-butanol, and E is water. The n-hexane part, chloroform part, ethyl acetate part, and n-butanol part of Magnolia floridulus all have certain inhibitory effects, while the inhibitory effect of the water-extracted part is generally poor.
[0068] n-Butane site: With the increase of concentration, the inhibition rate showed a trend of first slow and then rapid growth. The SW480 and SW620 cell lines showed higher inhibition rates, indicating that the n-hexane site had a strong inhibitory effect on these two cell lines.
[0069] Chloroform site: The inhibition rate increased steadily with the increase of concentration. The difference between the cell lines was relatively small. SW480 and SW620 still maintained a high inhibition rate level.
[0070] Ethyl acetate site: The inhibition rate increased significantly with the increase of concentration, and the growth trend among different cell lines was relatively consistent. The LoVo cell line showed the highest inhibition rate in this site.
[0071] n-Butanol site: The inhibition rate increased with the concentration, but the increase was relatively small. The inhibition rates among different cell lines varied greatly, among which LoVo and Caco-2 had relatively high inhibition rates.
[0072] In summary, the n-hexane part, chloroform part, ethyl acetate part, and n-butanol part of Magnolia floribunda all showed good dose-effect relationships, among which the chloroform part had the best inhibitory effect.
[0073] Example 5
[0074] This example further investigates the effect of chloroform site on the colony formation of colorectal cancer cells.
[0075] Digest and count the cells, inoculate 200-300 cells / well in a 12-well cell culture plate; after the cells form a cell colony of 3-4 cells, add different concentrations of magnolia extract chloroform site for 48 hours. Continue to observe and replace fresh complete culture medium every 2 days until cell colonies visible to the naked eye are formed. Carefully aspirate and discard the original culture medium, wash once with pre-cooled PBS buffer, and fix with appropriate amount of methanol for 15-20 minutes. After fixation, aspirate and discard the fixative, add appropriate amount of PBS buffer to wash once, and add appropriate amount of crystal violet stain for staining for 15-20 minutes. Wash twice with PBS buffer and clean water, dry the well plate, take pictures and count, and see the attached for specific results. Figure 3 shown.
[0076] By the attached Figure 3 The data shows that Figure 3 In the figure, A is HCT116, B is Caco-2, and MFC represents chloroform extract. The chloroform part has a significant inhibitory effect on the cloning of colon cancer cells HCT116 and Caco-2, and this inhibitory effect shows a concentration-dependent trend. As the concentration of the chloroform part increases, the number of cell clones gradually decreases, indicating that the chloroform part can effectively inhibit the proliferation and cloning of colorectal cancer cells. This result further confirms the potential application value of the chloroform part in the field of anti-cancer and provides a strong experimental basis for its subsequent research and development.
[0077] Example 6
[0078] This example investigates the effect of chloroform site on the cell cycle of colorectal cancer cells.
[0079] The cells were cultured at 2 × 10 5 Cells were seeded at a density of 1000 μL / well in a 6-well plate, and 1800 μL of culture medium was dispensed into each well. The plate was then placed in a cell culture incubator overnight. The next day, 200 μL of chloroform fractions of different concentrations were added to each well and cultured for 48 h.
[0080] Digest and collect cells into 1.5mL EP tubes, gently wash twice with pre-cooled PBS buffer, and discard the supernatant after centrifugation (3000rpm / min, 5min). Resuspend the cells with 1mL 70% cold ethanol and place at -20℃ overnight. Discard the cold ethanol solution after centrifugation (4000rpm / min, 5min), and gently wash twice with PBS buffer. Add 500μL 50μg / mL RNase inhibitor diluent to each tube and incubate at room temperature in the dark for 30min. Discard the RNase inhibitor diluent after centrifugation (4000rpm / min, 5min), and resuspend the cells in 500μL PBS buffer. Add 25μL 1.25mg / mL propidium iodide staining solution and incubate at room temperature in the dark for 30min. Detect using flow cytometer.
[0081] The regulatory effect of chloroform site on cyclin was investigated by Western blotting experiment. The cells in the 6-well plate were washed 3 times with PBS buffer, and 150 μL of RIPA lysis buffer containing protease inhibitors and phosphatase inhibitors was added. Lysis was carried out on ice for 30 minutes, and proteins were extracted. The protein concentration of each sample was determined by BCA protein quantitative detection kit. Mix evenly with protein loading buffer in proportion and boil for 5 minutes. Use 10% gel electrophoresis, cut the gel of the appropriate range of the corresponding protein indicated by the color pre-stained protein molecular weight standard, transfer to the membrane, block with 5% skim milk powder for more than 2 hours, add antibodies diluted in appropriate proportions, incubate at 4 degrees overnight, take out and reheat on the next day, and elute with TBST shaking for 3 times, each time for 5 minutes. Add secondary antibody, incubate at 37 degrees for 2 hours, and elute with TBST shaking for 3 times, each time for 5 minutes. Develop, take pictures with imaging system and analyze the optical density value of each band. For specific results, see the attached Figure 4-5 shown.
[0082] By the attached Figure 4 The data shows that Figure 4 In the figure, A is HCT116, B is Caco-2, and MFC represents chloroform extract. The chloroform fraction can significantly arrest the cell cycle of HCT116 and Caco-2 cells at the S phase. This finding suggests that the chloroform fraction affects the transition of cells from the S phase to the G2 / M phase by regulating the expression or activity of cyclins, thereby inhibiting cell proliferation.
[0083] By the attached Figure 5 The data shows that Figure 5 In the figure, A is HCT116, B is Caco-2, and MFC represents chloroform extract. The chloroform site can dose-dependently downregulate the protein expression of three cycle-related proteins, Cyclin E, Cyclin D, and CDK2, in HCT116 and Caco-2 cells. This means that with the increase in the concentration of the chloroform site, the expression levels of these cyclins gradually decrease, and the chloroform site effectively inhibits the proliferation of colorectal cancer cells. Due to the downregulation of Cyclin E, Cyclin D, and CDK2, the cell cycle of HCT116 and Caco-2 cells may be blocked in the G1 phase or the S phase. This is consistent with the flow cytometry results mentioned earlier (cell cycle blocked in the S phase).
[0084] Example 7
[0085] This example investigates the effect of chloroform site on apoptosis of colorectal cancer cells.
[0086] Annexin V-FITC / PI apoptosis kit (Shanghai Qihai Futai Biotechnology Co., Ltd.); Novocyte flow cytometer (Hangzhou Aisen Bioscience Co., Ltd.); ECL luminescent liquid (Anhui White Shark Biotechnology Co., Ltd.); Tanon 5200Multi automatic chemiluminescence image analysis system (Shanghai Tianneng Technology Co., Ltd.).
[0087] The cells were cultured at 2 × 10 5 Cells were inoculated in 6-well plates at a density of 1000 μL / well, and 1800 μL of culture medium was allocated to each well. After that, the plate was placed in a cell culture incubator overnight so that the cells could firmly adhere to the surface of the well plate. On the second day, 200 μL of different concentrations of magnolia extract were added to each well and cultured for 48 h. The cells in the 6-well plate were digested and collected, and the apoptotic cells in the culture medium were collected into EP tubes and washed 2-3 times with pre-cooled PBS. 400 μL 1×AnnexinV Binding Buffer was added to wash once, and the supernatant was discarded after centrifugation (2000 rpm / min, 5 min), and 400 μL 1×AnnexinV Binding Buffer was added to resuspend the cells. 5 μL CL488-AnnexinV and 10 μL PI were added and mixed under light-proof conditions, and placed on ice for 15 min. The apoptosis rate of cells was detected by selecting FITC-H and PE-H dual channels on a flow cytometer and the results were exported.
[0088] The regulatory effect of chloroform site on apoptotic proteins was investigated by Western blotting experiment. The cells in the 6-well plate were washed 3 times with PBS buffer, and 150 μL of RIPA lysis buffer containing protease inhibitors and phosphatase inhibitors was added. Lysis was performed on ice for 30 minutes, and proteins were extracted. The protein concentration of each sample was determined by BCA protein quantitative detection kit. Mix evenly with protein loading buffer in proportion and boil for 5 minutes. Use 10% gel electrophoresis, cut the gel of the appropriate range of the corresponding protein indicated by the color pre-stained protein molecular weight standard, transfer the membrane, block with 5% skim milk powder for more than 2 hours, add antibodies diluted in appropriate proportions, incubate at 4 degrees overnight, take out and reheat on the next day, and elute with TBST oscillation 3 times, each time for 5 minutes. Add secondary antibodies diluted in appropriate proportions, incubate at 37 degrees for 2 hours, and elute with TBST oscillation 3 times, each time for 5 minutes. Develop, take pictures with an imaging system and analyze the optical density values of each band. For specific test results, see the attached Figure 6 and attached Figure 7 shown.
[0089] By the attached Figure 6 The data shows that Figure 6In the figure, A is HCT116, B is LoVo, C is a quantitative graph of HCT116 cell apoptosis, D is a quantitative graph of LoVo cell apoptosis, and MFC represents chloroform extract. Compared with the control group, the chloroform fraction prepared in Example 2 can significantly induce apoptosis of HCT116 and LoVo cells. This indicates that the chloroform fraction has the activity of promoting apoptosis of colorectal cancer cells.
[0090] By the attached Figure 7 The data shows that Figure 7 In the figure, A is HCT116, B is LoVo, and MFC represents chloroform extract. The chloroform fraction can downregulate the expression of anti-apoptotic protein Bcl-2 and upregulate the expression of pro-apoptotic protein Bax in HCT116 and LoVo cells in a concentration-dependent manner. This finding provides direct evidence for the mechanism by which the chloroform fraction induces cell apoptosis.
[0091] In summary, Bcl-2 is an important anti-apoptotic protein that prevents apoptosis by inhibiting key enzymes in the apoptotic pathway (such as Caspase). Bax is a pro-apoptotic protein that can form heterodimers with Bcl-2, thereby inhibiting the anti-apoptotic effect of Bcl-2. Therefore, a decrease in the Bcl-2 / Bax ratio is usually associated with an increase in apoptosis. The chloroform site breaks the intracellular Bcl-2 / Bax balance by downregulating Bcl-2 and upregulating Bax expression, thereby promoting apoptosis. The chloroform site is an active ingredient in magnolia extract, and its potential to induce apoptosis in colorectal cancer cells provides a new idea for the treatment of colorectal cancer.
[0092] Example 8
[0093] This example investigates the effect of chloroform site on the migration of colorectal cancer cells.
[0094] The cells were plated at 5×10 5 Cells were inoculated at a density of 100 μl / well in a 12-well plate, and 900 μl of culture medium was allocated to each well. When the cell growth density reached about 90%, scratched with a 200 μl pipette tip, and carefully washed twice with PBS buffer to remove the suspended cells. 3% low-serum culture medium was added. The 12-well plate was placed under an inverted microscope for bright-field photography, and the photography position was marked on the lid of the well plate. This photography was recorded as 0h. Next, different concentrations of chloroform fractions of magnolia extract were added to the treatment group, and photos were taken at fixed positions 48 hours after the drug action and recorded. For specific results, please see the attached appendix. Figure 8 and attached Fig. 9 shown.
[0095] By the attached Figure 8 The data shows that Figure 8In the figure, A is HCT116, B is LoVo, and MFC represents chloroform extract. E-Cadherin is a calcium-dependent cell-cell adhesion molecule that is essential for maintaining the integrity and polarity of epithelial cells. Its upregulation is usually associated with enhanced cell-cell adhesion and weakened migration ability. Compared with the control group, the chloroform site upregulated the expression of E-Cadherin and inhibited the migration of colorectal cancer cells by enhancing cell-cell adhesion.
[0096] By the attached Fig. 9 The data shows that Fig. 9 In the figure, A is HCT116, B is LoVo, and MFC represents chloroform extract. N-Cadherin and Vimentin are mesenchymal cell markers and are closely related to the epithelial-mesenchymal transition (EMT) process. EMT is an important way for tumor cells to acquire migration and invasion capabilities. Down-regulating the expression of N-Cadherin and Vimentin in the chloroform site may reduce the migration and invasion of colorectal cancer cells by inhibiting the EMT process.
[0097] In summary, the chloroform site upregulates the expression of E-Cadherin, downregulates the expression of N-Cadherin and Vimentin, and simultaneously acts on multiple molecular targets to jointly inhibit the migration ability of colorectal cancer cells.
[0098] Example 9
[0099] The CT26 cell line is a commonly used colorectal cancer cell model, which is often used in in vitro and in vivo experiments to evaluate the effects of drugs on tumor growth. This example investigates the inhibitory effect of chloroform fraction on the growth of CT26 in a Balb / c mouse transplant tumor model.
[0100] CT26 cells with good growth status were collected in EP tubes, centrifuged (1000 rpm / min, 5 min), the supernatant was discarded, washed once with pre-cooled PBS, centrifuged (1000 rpm / min, 5 min), the supernatant was discarded, resuspended with physiological saline and the cells were counted. 5×10 4 After inoculation, the mice's condition and the growth of transplanted tumors were closely observed, and the average tumor volume reached 100mm 3 The mice were randomly divided into a control group (n=5) and a drug-treated group (n=5). The control group was gavaged with 0.2 mL of saline daily, and the drug-treated group was gavaged with 0.2 mL of drugs of different concentrations for 14 consecutive days. After the drug administration, the mice were killed by cervical dislocation, and the tumor tissues were taken, weighed, and photographed. The specific results are shown in the attached Fig.10 shown.
[0101] By the attached Fig.10 The results show that the attached Fig.10 In the figure, A is the tumor weight, and B is the relationship between the tumor inhibition effect and the drug concentration. Through 14 consecutive days of drug administration observation, compared with the control group, the tumor growth of the mice in the chloroform part administration group prepared in Example 2 was significantly inhibited, and this inhibitory effect became more significant with the increase of drug concentration. Compared with the control group (Ctrl group), the tumor weight of the drug administration group (MFC group) was significantly reduced, especially at a drug concentration of 200 mg / kg, the tumor weight was reduced to the minimum, about one-third of the control group, which shows that the chloroform part shows a good tumor inhibition effect in the Balb / c mouse CT26 transplanted tumor model, and its tumor inhibition effect is positively correlated with the drug concentration. The chloroform part is expected to become a potential effective drug component in the treatment of colorectal cancer.
[0102] Embodiment 11
[0103] This example investigates the effect of chloroform site on the PI3K pathway
[0104] The cells were cultured at 2 × 10 4 Seed the cells / well in a 96-well plate and distribute 180 μL of culture medium to each well. Place the plate in a cell culture incubator overnight. On the second day, add 20 μL of different treatments to each well and continue to culture for 48 hours. Aspirate the original culture medium, add culture medium containing 0.5 mg / mL MTT, and incubate in a light-proof 37°C incubator for 4-6 hours. Aspirate the liquid in the culture wells, add 100 μL / well of DMSO solution, place the well plate on a shaker at 180 rpm, and shake for 15 minutes. Use a spectrophotometer to detect the absorbance value.
[0105] Western blotting experiments were used to investigate the regulatory effect of chloroform sites on PI3K-AKT pathway proteins. The cells in the 6-well plate were washed 3 times with PBS buffer, and 150 μL of RIPA lysis buffer containing protease inhibitors and phosphatase inhibitors was added. Lysis was performed on ice for 30 minutes, and proteins were extracted. The protein concentration of each sample was determined using a BCA protein quantitative detection kit. Mix evenly with the protein loading buffer in proportion and boil for 5 minutes. Use 10% gel electrophoresis, cut the gel of the appropriate range of the corresponding protein indicated by the color pre-stained protein molecular weight standard, transfer the membrane, block with 5% skim milk powder for more than 2 hours, add antibodies diluted in an appropriate proportion, incubate at 4 degrees overnight, and elute with TBST oscillation 3 times, each time for 5 minutes. Add secondary antibodies diluted in an appropriate proportion, incubate at 37 degrees for 2 hours, and elute with TBST oscillation 3 times, each time for 5 minutes. Develop, take pictures with a gel imaging system and analyze the optical density values of each band.
[0106] The test results are shown in the attached Fig.11 -Attached Fig.14 shown.
[0107] PI3K (phosphatidylinositol 3-kinase) is a key signal transduction enzyme that plays an important role in multiple processes such as cell growth, proliferation, survival and metabolism. p110α is a catalytic subunit of PI3K, and its abnormal expression or activation is closely related to the occurrence and development of various cancers, including colon cancer. Fig.11 The results show that the attached Fig.11 In the table, A is the expression level and B is the IC 50 The correlation analysis diagram shows that as the concentration of the chloroform site increases, the expression level of PI3Kp110α shows a downward trend, and the growth inhibition rate of colon cancer cells gradually increases. This indicates that the chloroform site inhibits the growth of colon cancer cells by inhibiting the expression of PI3Kp110α.
[0108] By the attached Fig.12 The results showed that the chloroform site could inhibit the protein levels of PI3Kp110α and p-AKT, and the chloroform site could inhibit the PI3K-AKT signaling pathway.
[0109] By the attached Fig.13 The results show that the attached Fig.13 In the figure, A is the expression graph of PI3Kp110α, and B is the inhibitory effect of the chloroform site on the growth of colorectal cancer cells HCT116 with PIK3CA knockdown. In HCT116 cells with PI3Kp110α knockdown, the proliferation inhibitory effect of the chloroform site prepared in Example 2 was weakened, indicating that the target of the chloroform site is PI3Kp110α.
[0110] By the attached Fig.14 The results show that the attached Fig.14 In the figure, A is the expression of PI3Kp110α, B is the inhibitory effect of chloroform on the growth of PIK3CA wild-type and H1047R mutant cells, and IC of chloroform on PIK3CA Vector, WT, and H1047R mutant HEK293 cells 50 They were 0.8302, 0.5846, and 0.3691 mg / mL, respectively, indicating that the chloroform site had a more significant inhibitory effect on cell proliferation of the PIK3CA-H1047R mutation.
[0111] In summary, the chloroform fraction of total magnolia alkaloids effectively inhibited the proliferation of colon cancer cells by inhibiting the expression of PI3Kp110α and downstream AKT protein. In addition, the chloroform fraction had a stronger proliferation inhibitory effect on cells with PIK3CA mutations. Therefore, total magnolia alkaloids have potential application value in the treatment of PIK3CA mutant tumors.
[0112] Example 12
[0113] This example mainly analyzes the components of the methanol extract of Magnolia officinalis in Example 1 and the chloroform part in Example 2 of the present invention.
[0114] The liquid phase conditions mainly include: chromatographic column: Agilent SB-C181.8μm, 2.1mm*100mm; mobile phase: phase A is ultrapure water (added with 0.1% formic acid), phase B is acetonitrile (added with 0.1% formic acid); elution gradient: 0.00min B phase ratio is 5%, within 9.00min, the B phase ratio linearly increases to 95%, and maintains at 95% for 1min, 10.00-11.10min, the B phase ratio is reduced to 5%, and balanced at 5% for 14min; flow rate 0.35mL / min; column temperature 40℃; injection volume 2μL. The mass spectrometry conditions mainly include: electrospray ionization (ESI) temperature 550°C; ion spray voltage (IS) 5500 V (positive ion mode) / -4500 V (negative ion mode); ion source gas I (GSI), gas II (GSII) and curtain gas (CUR) were set to 50, 60 and 25 psi respectively, and the collision-induced ionization parameter was set to high.
[0115] For detailed results, please see the attached Figure 15-16 shown.
[0116] By the attached Fig.15 The data shows that Fig.15 In the figure, A is the methanol extract and B is the chloroform fraction. UPLC-MS / MS total ion chromatograms of the methanol extract and chloroform fraction of Magnolia officinalis showed that a total of 1878 compounds were detected.
[0117] By the attached Fig.16 The data show that the heat map of the differential components between the methanol extract and the chloroform part of Magnolia officinalis showed that the proportion of alkaloid components enriched in the chloroform part increased, indicating that alkaloids may be the active components of the chloroform part that exert anti-colorectal cancer effects.
[0118] Embodiment 13
[0119] This example investigates the inhibitory effects of chloroform fraction and total alkaloids of Magnolia officinalis on the growth and metastasis of HCT116 nude mouse transplanted tumors
[0120] Total alkaloid thin layer chromatography analysis: Use a microsyringe to spot the extract solution on a thin layer chromatography silica gel G plate and dry it at room temperature. Prepare a developing chamber and add a developing agent (chloroform-methanol-water, 13:7:2). Place the spotted thin layer plate in the developing chamber for development. Use potassium bismuth iodide solution for color development to make the alkaloid spots visible.
[0121] Collect HCT116 cells with good growth status in EP tubes, centrifuge (1000rpm / min, 5min) and discard the supernatant, wash once with pre-cooled PBS, centrifuge (1000rpm / min, 5min) and discard the supernatant, and finally resuspend with saline and count. Inject 2.5×106 cells subcutaneously under the left armpit of each male Balb / c nude mouse. After inoculation, the health status of the mice and the development of the transplanted tumor need to be closely monitored. The volume of the transplanted tumor reaches 20mm 3 The mice were randomly divided into a control group, a chloroform site (MFC) administration group (200 mg / kg), and a total alkaloid (Total alkaloid) administration group (200 mg / kg), with 5 mice in each group. The control group was gavaged with 0.2 mL of normal saline every day, and the drug group was gavaged with 0.2 mL of the drug every day for 14 consecutive days. During this period, the weight of the mice, the long diameter and short diameter of the transplanted tumor were measured every day. After the experiment, the mice were killed. The mice were dissected, the main tissues and organs were taken, and the tumor tissue and liver tissue were photographed and recorded. For specific results, please refer to the attached Fig.17 -Attached Fig.19 shown.
[0122] By the attached Fig.17 The results show that the total alkaloid extract of magnolia was identified by an alkaloid-specific colorimetric agent, and the total alkaloid extract of magnolia changed color with the alkaloid-specific colorimetric agent, confirming the presence of alkaloid components in the total alkaloid extract of magnolia, indicating that the alkaloid extract of magnolia of the present invention was successfully prepared.
[0123] By the attached Fig.18 The results show that the attached Fig.18 In the figure, A is a tumor photo and B is a tumor weight graph. Compared with the control group, the chloroform part and magnolia total alkaloids administration groups can significantly inhibit the growth of HCT116 tumors. The data points of the chloroform part (MFC) and magnolia total alkaloids (Total alkaloids) administration groups are significantly left-leaning and lower, indicating that both treatments can effectively inhibit the growth of HCT116 tumors. This inhibitory effect is manifested as a significant reduction in tumor weight; and the magnolia total alkaloids group has a better growth inhibition effect than the chloroform part.
[0124] By the attached Fig.19 The results show that the attached Fig.19 In the figure, A is a liver photo and B is a liver coefficient diagram. Compared with the control group, the chloroform part and magnolia total alkaloids administration group can significantly inhibit the liver metastasis of HCT116 tumor, and the total magnolia alkaloids group has a better inhibitory effect on metastasis than the chloroform part.
[0125] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modifications to equivalent embodiments of equivalent changes by using the methods and technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still falls within the scope of the technical solution of the present invention.
Claims
1. A method for preparing a total alkaloid extract of Magnolia officinalis for resisting tumors containing PIK3CA mutations, characterized in that: include: (1) crushing magnolia flower, extracting with pure methanol by refluxing, filtering, and evaporating to dryness to obtain magnolia flower methanol extract; (2) taking the magnesium methanol extract obtained in step (1), adding distilled water for ultrasonic dispersion, adjusting the pH value to obtain a first solution, and performing fractional extraction to obtain a magnesium extract; (3) Taking the extract of magnolia officinalis extracted in step (2), adjusting the pH value to obtain a second solution, extracting again, and evaporating to obtain a magnolia officinalis total alkaloid extract for anti-tumor containing PIK3CA mutation.
2. The method for preparing the total alkaloid extract of Magnolia officinalis for resisting tumors containing PIK3CA mutation according to claim 1, characterized in that: The pure methanol reflux extraction is performed, and the amount of pure methanol solution added is 15 to 25 times the mass of magnolia, and the pure methanol reflux extraction time is 2 hours to 4 hours.
3. The method for preparing the total alkaloid extract of Magnolia officinalis for resisting tumors containing PIK3CA mutation according to claim 1, characterized in that: The distilled water is added for ultrasonic dispersion, and the amount of distilled water added is 10 to 20 times the mass of the magnolia methanol extract.
4. The method for preparing the total alkaloid extract of Magnolia officinalis for resisting tumors containing PIK3CA mutation according to claim 1, characterized in that: The graded extraction solvents are n-hexane, chloroform, ethyl acetate and n-butanol in sequence, the added amount of the extraction solvent is 1:1 in volume ratio with the first solution, and the number of extractions is 8-10 times.
5. The method for preparing the total alkaloid extract of Magnolia officinalis for resisting tumors containing PIK3CA mutation according to claim 1, characterized in that: The re-extraction solvent in step (3) is dichloromethane, the volume ratio of dichloromethane added to the second solution is 10-15:1, and the number of extractions is 8-10 times.
6. The method for preparing the total alkaloid extract of Magnolia officinalis for resisting tumors containing PIK3CA mutation according to claim 4, characterized in that: In step (2), the pH value is adjusted to 2-3, and in step (3), the pH value is adjusted to 9-11.
7. The total alkaloid extract of Magnolia officinalis obtained by the preparation method according to any one of claims 1 to 6 for resisting tumors containing PIK3CA mutations.
8. The use of the total alkaloid extract of magnolia floridula in the preparation of a drug for treating tumors containing PIK3CA mutations according to claim 7, characterized in that: The tumor is selected from any one of breast cancer, endometrial cancer, cervical cancer, anal cancer, bladder cancer, and colorectal cancer.
9. The use according to claim 8, characterized in that: The anti-tumor containing PIK3CA mutation is to inhibit tumor cell proliferation, block cell cycle, inhibit clone formation, induce cell apoptosis and inhibit cell migration, and inhibit tumor cell growth in vivo.
10. The use according to claim 8, characterized in that: The anti-tumor drug containing PIK3CA mutation is any one of pills, granules, hard capsules, soft capsules, tablets, dripping pills and oral liquid preparations.
Citation Information
Patent Citations
Medical application of fargesin
CN103040805A
Cynanchum komarovii total alkaloid and preparing method and application thereof
CN103446211A
Pharmaceutical composition for preventing and treating chronic obstructive lung disease containing, as active ingredient, magnoliae flos extract, fraction, or active fraction thereof
CN108135954A
Method for constructing UPLC characteristic chromatogram of biond-magnolia-flower formula granules and determination of content of biond-magnolia-flower formula granules
CN111089930A
Application of melodinus axillaris in preparation of anti-tumor medicine
CN117427097A
